SUMM.L Share News (SUMM)

Summit Therapeutics widens loss as drug development continues

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its financial results for the third quarter to 31 October on Thursday. The AIM-traded firm had cash and cash equivalents at period end of £34.6m compared to £16.3m on 31 January. Its loss for the nine months was £1

Summit Therapeutics enrols first US patients in ezutromid trial for DMD

(ShareCast News) - AIM-listed drug discovery and development company Summit Therapeutics has enrolled its first patients in phase II proof of concept trials in the US of ezutromid in patients with Duchenne muscular dystrophy. Summit said enrolment and dosing of patients into Phase Out DMD in the UK

Summit Therapeutics shares plummet despite positive progress

(ShareCast News) - Drug discovery and development company Summit Therapeutics presented preclinical data at the 21st International Congress of the World Muscle Society in Granada, Spain on Thursday, including further findings from its programme to develop tools to measure biomarkers of muscle health

BUZZ-Summit Therapeutics: Best day since 2009 on Sarepta deal

** Shares in drug developer Summit Therapeutics up 58 pct after teams up with US drug co Sarepta Therapeutics to develop and market DMD drug in Europe ** Stock poised for its best day since April 2009 ** Co gets $40 mln upfront payment, could receive up to $522 million in milestone p

Summit Therapeutics Sees Positive Phase I Trial Results For Ezutromid

Summit Therapeutics Shows Further Positive Trial Data For Ridinilazole

Summit Therapeutics Enrols First Patient In Phase II Ezutromid Trial

Cash reduced, losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics posted its first quarter results on Thursday, with cash reduced and losses widening. The AIM-traded firm, which is advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), had cash and ca

Losses widen at Summit Therapeutics

(ShareCast News) - Drug discovery and development company Summit Therapeutics reported an increase in cash and activities in its full-year results on Tuesday, though its losses widened as it carried its projects towards commercialisation. The AIM-traded firm had cash and cash equivalents of £16.3m o

Summit Therapeutics Posts Widened Loss As It Progresses Programmes

Summit Therapeutics Gets Further US Patent For Antibiotic Ridinlazole

Summit Therapeutics Gets Clearance To Expand Ezutromid Trial To US

Summit reports positive results from Duchenne muscular dystrophy treatment

(ShareCast News) - Summit Therapeutics reported positive interim findings on Wednesday, from a recent Phase 1 trial of a new oral formulation of its SMT C1100 therapy for Duchenne muscular dystrophy. The AIM-traded drug discovery and development company focuses on advancing therapies for Duchenne mu

Summit Therapeutics Gets Positive Interim SMT C1100 Test Results

Summit Therapeutics Sees Further Positive Data For Ridinilazole